Duyuru • Jun 30
Huapont Life Sciences Co.,Ltd. to Report First Half, 2026 Results on Aug 20, 2026 Huapont Life Sciences Co.,Ltd. announced that they will report first half, 2026 results on Aug 20, 2026 Duyuru • Jun 10
Huapont Life Sciences Co.,Ltd. Announces Cash Dividend on A Shares for 2025, Payable on 16 June 2026 Huapont Life Sciences Co.,Ltd. announced Cash dividend/10 shares (tax included) CNY 2.50000000 on A shares for 2025. Record date: 15 June 2026. Ex-date: 16 June 2026. Payment date: 16 June 2026. Reported Earnings • Apr 24
Full year 2025 earnings released: EPS: CN¥0.36 (vs CN¥0.15 loss in FY 2024) Full year 2025 results: EPS: CN¥0.36 (up from CN¥0.15 loss in FY 2024). Revenue: CN¥11.5b (down 1.3% from FY 2024). Net income: CN¥713.2m (up CN¥1.01b from FY 2024). Profit margin: 6.2% (up from net loss in FY 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Duyuru • Apr 23
Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026 Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026, at 13:30 China Standard Time. Location: No. 69, Xingguang Avenue, Renhe, Yubei District, Chongqing China Duyuru • Mar 31
Huapont Life Sciences Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Duyuru • Dec 31
Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.07 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.11 (up from CN¥0.07 in 3Q 2024). Revenue: CN¥3.14b (up 5.1% from 3Q 2024). Net income: CN¥223.4m (up 61% from 3Q 2024). Profit margin: 7.1% (up from 4.6% in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Oct 17
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to CN¥5.01. The fair value is estimated to be CN¥3.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 6.1% over the last 3 years. Meanwhile, the company became loss making. Duyuru • Sep 30
Huapont Life Sciences Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Buy Or Sell Opportunity • Sep 24
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 9.2% to CN¥4.53. The fair value is estimated to be CN¥3.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 6.1% over the last 3 years. Meanwhile, the company became loss making. Duyuru • Sep 09
Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025 Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025. New Risk • Aug 23
New minor risk - Dividend sustainability The dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 8.1% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 39% per year over the past 5 years. Minor Risk Paying a dividend despite being loss-making. Reported Earnings • Aug 22
Second quarter 2025 earnings released: EPS: CN¥0.10 (vs CN¥0.08 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.10 (up from CN¥0.08 in 2Q 2024). Revenue: CN¥3.12b (up 3.9% from 2Q 2024). Net income: CN¥204.1m (up 29% from 2Q 2024). Profit margin: 6.5% (up from 5.3% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Duyuru • Aug 21
Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution Plan Huapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025. Duyuru • Jul 02
Huapont Life Sciences Co.,Ltd. to Report First Half, 2025 Results on Aug 20, 2025 Huapont Life Sciences Co.,Ltd. announced that they will report first half, 2025 results on Aug 20, 2025 Board Change • Jun 07
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • May 16
Huapont Life Sciences Co.,Ltd. Approves the Election of Zhang Songshan as Non-Independent Director Huapont Life Sciences Co.,Ltd. at its Annual General Meeting held on 14 May 2025 approved the election of Zhang Songshan as non-independent director. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.093 (vs CN¥0.079 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.093 (up from CN¥0.079 in 1Q 2024). Revenue: CN¥2.82b (down 3.2% from 1Q 2024). Net income: CN¥184.3m (up 19% from 1Q 2024). Profit margin: 6.5% (up from 5.3% in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Duyuru • Apr 23
Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025 Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China Duyuru • Mar 31
Huapont Life Sciences Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025 Duyuru • Dec 31
Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025 Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.059 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.059 in 3Q 2023). Revenue: CN¥2.99b (flat on 3Q 2023). Net income: CN¥138.5m (up 18% from 3Q 2023). Profit margin: 4.6% (up from 3.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Duyuru • Sep 30
Huapont Life Sciences Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥4.75, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 22% over the past three years. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.11 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.11 in 2Q 2023). Revenue: CN¥3.01b (up 3.9% from 2Q 2023). Net income: CN¥158.0m (down 25% from 2Q 2023). Profit margin: 5.3% (down from 7.3% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Duyuru • Jun 29
Huapont Life Sciences Co.,Ltd to Report First Half, 2024 Results on Aug 31, 2024 Huapont Life Sciences Co.,Ltd announced that they will report first half, 2024 results on Aug 31, 2024 Declared Dividend • May 30
Dividend of CN¥0.22 announced Dividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.7%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend. Duyuru • May 29
Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024 Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000). Duyuru • May 26
Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023 Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023. Duyuru • Apr 29
Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024 Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.09 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.079 (down from CN¥0.09 in 1Q 2023). Revenue: CN¥2.92b (down 2.0% from 1Q 2023). Net income: CN¥155.6m (down 12% from 1Q 2023). Profit margin: 5.3% (down from 6.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Duyuru • Mar 30
Huapont Life Sciences Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024 Huapont Life Sciences Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024 Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥4.50, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 2.4% over the past three years. Board Change • Dec 22
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.079 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.059 (down from CN¥0.079 in 3Q 2022). Revenue: CN¥2.98b (down 14% from 3Q 2022). Net income: CN¥117.8m (down 25% from 3Q 2022). Profit margin: 3.9% (down from 4.5% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.20 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.20 in 2Q 2022). Revenue: CN¥2.89b (down 12% from 2Q 2022). Net income: CN¥210.0m (down 46% from 2Q 2022). Profit margin: 7.3% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Duyuru • Jun 09
Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023 Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023. Duyuru • May 19
Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022 Huapont Life Sciences Co.,Ltd approved final cash dividend per 10 shares (tax included) of CNY 2.20000000 for the year 2022 at its Annual General Meeting of 2022 on 17 May 2023. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.09 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥2.98b (down 13% from 1Q 2022). Net income: CN¥177.1m (up 5.0% from 1Q 2022). Profit margin: 6.0% (up from 5.0% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat. Buying Opportunity • Apr 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.1%. The fair value is estimated to be CN¥6.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last year. Earnings per share has grown by 32%. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 31
Third quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.08 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.079 (down from CN¥0.08 in 3Q 2021). Revenue: CN¥3.48b (up 21% from 3Q 2021). Net income: CN¥157.1m (down 6.2% from 3Q 2021). Profit margin: 4.5% (down from 5.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.20 (up from CN¥0.12 in 2Q 2021). Revenue: CN¥3.30b (up 13% from 2Q 2021). Net income: CN¥391.3m (up 69% from 2Q 2021). Profit margin: 12% (up from 7.9% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥6.12, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 44% over the past three years. Duyuru • May 28
Huapont Life Sciences Co., Ltd. Announces Dividend on A Shares for the Year 2021, Payable on June 2, 2022 Huapont Life Sciences Co., Ltd. announced final profit distribution on A shares of CNY 2.20000000 per ten shares (tax included) for the year 2021. Record date is 01 June 2022. Ex-date is 02 June 2022. Payment date is 02 June 2022. Reported Earnings • May 02
First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.06 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.085 (up from CN¥0.06 in 1Q 2021). Revenue: CN¥3.40b (up 21% from 1Q 2021). Net income: CN¥168.6m (up 39% from 1Q 2021). Profit margin: 5.0% (up from 4.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Apr 14
Huapont Life Sciences Co., Ltd. Approves Profit Distribution for 2021 Huapont Life Sciences Co., Ltd. approved profit distribution /10 shares (tax included): CNY 2.20000000 for 2021 at its Annual General Meeting held on 12 April 2022. Duyuru • Mar 23
Huapont Life Sciences Co., Ltd., Annual General Meeting, Apr 12, 2022 Huapont Life Sciences Co., Ltd., Annual General Meeting, Apr 12, 2022, at 14:00 China Standard Time. Agenda: To consider the 2021 work report of the board of directors; to consider the 2021 work report of the supervisory committee; to consider the 2021 annual accounts; to consider the 2021 profit distribution plan; to consider the 2021 annual report and its summary; to consider the 2021 special report on the deposit and use of raised funds; to consider the reappointment of 2022 audit firm and to consider the provision of financial aid to a hospital. Reported Earnings • Feb 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥0.34 (up from CN¥0.33 in FY 2020). Revenue: CN¥12.4b (up 14% from FY 2020). Net income: CN¥670.0m (up 2.8% from FY 2020). Profit margin: 5.4% (down from 6.0% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥7.40, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 65% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.10 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥2.88b (up 6.4% from 3Q 2020). Net income: CN¥167.5m (down 15% from 3Q 2020). Profit margin: 5.8% (down from 7.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥6.85, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥7.44, the stock trades at a trailing P/E ratio of 21.3x. Average trailing P/E is 32x in the Chemicals industry in China. Total returns to shareholders of 72% over the past three years. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020) The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: CN¥2.93b (flat on 2Q 2020). Net income: CN¥231.5m (down 1.3% from 2Q 2020). Profit margin: 7.9% (down from 8.0% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.82b (up 25% from 1Q 2020). Net income: CN¥121.6m (up 47% from 1Q 2020). Profit margin: 4.3% (up from 3.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 7.8% from FY 2019). Net income: CN¥651.7m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 8.4% from FY 2019). Net income: CN¥652.1m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses. Duyuru • Feb 24
Huapont Life Sciences Co., Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021 Huapont Life Sciences Co., Ltd. announced that they will report fiscal year 2020 results on Apr 01, 2021 Is New 90 Day High Low • Jan 25
New 90-day low: CN¥5.02 The company is down 1.0% from its price of CN¥5.08 on 27 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period. Is New 90 Day High Low • Dec 14
New 90-day high: CN¥6.06 The company is up 13% from its price of CN¥5.37 on 15 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 17
New 90-day high: CN¥5.71 The company is up 2.0% from its price of CN¥5.62 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 4.0% over the same period. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥627.2m, up 19% from the prior year. Total revenue was CN¥10.5b over the last 12 months, up 2.7% from the prior year. Is New 90 Day High Low • Sep 24
New 90-day low: CN¥5.18 The company is down 2.0% from its price of CN¥5.26 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.